<DOC>
	<DOCNO>NCT01380327</DOCNO>
	<brief_summary>This trial follow-up study ICAC-12 Phase I/II trial ( NCT00829985 ) , design study biomarkers immune response allergen immunotherapy safety therapy pediatric population .</brief_summary>
	<brief_title>Biomarkers Cockroach Sublingual Immunotherapy 2</brief_title>
	<detailed_description>Over past two decade , scientific evidence show combination cockroach allergy cockroach exposure one important factor contribute dramatic increase asthma morbidity see inner city child asthma . Therefore , major goal National Institute Allergy Infectious Diseases ( NIAID ) Inner City Asthma Consortium ( ICAC ) ultimately conduct large multi-center trial cockroach sublingual immunotherapy ( SLIT ) inner-city asthma . As step toward achieve goal , ICAC conduct clinical trial compare two dos glycerinated German cockroach ( Blattella germanica ) allergenic extract placebo , administer tongue ( sublingual ) .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Perennial</mesh_term>
	<criteria>Have history perennial allergic rhinitis , asthma , , study entry . For asthma : 1. diagnosis asthma define report participant clinical diagnosis asthma make physician year ago 2. participant 's asthma must well control define : ii . forced expiratory volume one second ( FEV1 ) great equal 80 % predict value without controller medication ii . albuterol use 3 day per week previous 2 week asthma symptom ( include exercise prophylaxis ) Are sensitive German cockroach ( Blattella germanica ) document positive ( &gt; /=3 mm great negative control ) skin prick test result detectable German cockroach specific IgE ( &gt; /=0.35 kUA/L ) Have know contraindication therapy glycerinated German cockroach allergenic extract placebo Parent legally authorize representative ( LAR ) child willing sign write Informed Consent prior initiation study procedure Are pregnant lactating . Females must abstinent use medically acceptable birth control method throughout study ( e.g . oral , subcutaneous , mechanical , surgical contraception ) Can perform spirometry peak flow screen Have asthma severity classification recruitment severe persistent , use National Asthma Education Prevention Program ( NAEPP ) classification , evidence least one following : 1. require dose great 500 mcg fluticasone per day equivalent another inhaled corticosteroid 2. receive 2 course oral parenteral corticosteroid within last 12 month 3. treat depot steroid within last 12 month 4. hospitalize asthma within 6 month prior recruitment 5. lifethreatening asthma exacerbation require intubation , mechanical ventilation , result hypoxic seizure within 2 year prior recruitment Do access phone ( need scheduling appointment ) Have receive allergen immunotherapy last 12 month prior recruitment plan initiate resume allergen immunotherapy study Have previously treat antiIgE therapy within 1 year recruitment Have receive investigational drug 30 day prior recruitment plan use investigational drug study Have last 3 month prior recruitment experienced average &gt; /=1 day per week symptom : 1. nausea vomit 2. abdominal pain cramp severe enough interfere daily activity ( exclude associate menstruation ) . 3. diarrhea Refuse sign Epinephrine Autoinjector Training Form Participants meet follow criterion eligible enrollment may reassess . Participants ineligible : Do primarily speak English Plan move area study period Have history idiopathic anaphylaxis anaphylaxis grade 2 high Have unstable angina , significant arrhythmia , uncontrolled hypertension , history autoimmune disease , chronic immunological disease opinion investigator might interfere evaluation investigational agent pose additional risk patient ( e.g. , gastrointestinal disease , gastroesophageal reflux disease , chronic infection , scleroderma , hepatic , gallbladder disease ) Are use tricyclic antidepressant betaadrenergic blocker drug ( either oral and/or topical route [ ] administration )</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>cockroach</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>sublingual immunotherapy ( SLIT )</keyword>
	<keyword>inner city asthma</keyword>
</DOC>